Angiotensin-converting enzyme inhibitor treatment after myocardial infarction. A selective approach for maximum benefit.

Early survival following myocardial infarction (MI) has improved significantly over the past 20 years, due in part to medical treatments including thrombolysis, aspirin and beta-blockade. Now, more MI survivors are at risk from the subsequent development of heart failure [(1)][1]. The clinical

[1]  F. Van de Werf,et al.  Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. The European Cooperative Study Group. , 1995, Circulation.

[2]  H. White,et al.  Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. , 1994, Circulation.

[3]  R M Whitlock,et al.  Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. , 1987, Circulation.

[4]  F. Hobbs.  The scale of heart failure: diagnosis and management issues for primary care , 1999, Heart.

[5]  G. Lamas,et al.  Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators. , 1995, Circulation.

[6]  M. Sutton,et al.  Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: results of a meta-analysis of 845 patients. FAMIS, CAPTIN and CATS Investigators. , 2000, Journal of the American College of Cardiology.

[7]  H. White,et al.  Effects of early captopril administration after thrombolysis on regional wall motion in relation to infarct artery blood flow. , 1999, Journal of the American College of Cardiology.

[8]  G. Murray,et al.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .

[9]  R. Collins,et al.  Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. , 1998, Circulation.

[10]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction , 1994, The Lancet.

[11]  N. Sharpe,et al.  TREATMENT OF PATIENTS WITH SYMPTOMLESS LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 1988, The Lancet.

[12]  Miles Be,et al.  Letter: Serum-phenytoin. , 1976 .

[13]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[14]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[15]  E. Topol,et al.  A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction. , 1991, Journal of the American College of Cardiology.

[16]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[17]  H. Crijns,et al.  Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: Results of a meta-analysis of 845 patients , 2001 .

[18]  G. Lamas,et al.  Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. , 1988, The New England journal of medicine.

[19]  G. Gamble,et al.  Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition , 1991, The Lancet.